2001 JAN 25 - (NewsRx.com & NewsRx.net) -- Cerus Corporation and Baxter Healthcare Corporation announced January 2, 2001, that they have submitted a CE Mark application for approval to market the Intercept Platelet System in Europe.
The system is designed to inactivate viruses, bacteria, other pathogens, and white blood cells in platelets intended for transfusion. If approved, the Intercept Platelet System will be the only system commercially available to enhance the safety of platelet transfusions through pathogen inactivation.
"We look forward to the approval of the Intercept Platelet System and working with Baxter to launch the first system to inactivate …
No comments:
Post a Comment